Skip to content
GLP-1 Scorecard
Menu
Graded #252

Hers

Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.

Visit HersWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
$199/mo (starting dose, compounded)
Tirzepatide
$299/mo (starting dose, plus a separate fee, brand-name)
Coverage
All 50 states
Brand-name
Yes

Weigh Hers against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value54/100
Dose & formulation77/100
Clinical oversight71/100
Labs & monitoring52/100
Fulfillment81/100
Contract terms41/100

Strengths

  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details

Bottom line — Grade C

Best for: Shoppers who want mainstream telehealth GLP-1 access.

Ranked #252 of 499 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

Closest on the board

The boards grading nearest Hers — the realistic shortlist.

The 21 boards nearest this one

View full scorecard rankings →

Pricing/verification reflect Hers's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Hers's site. Not medical advice; see our disclosure.

← Back to the scorecard